<?xml version="1.1" encoding="utf-8"?>
<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">JMDS</journal-id><journal-title-group><journal-title>Journal of Medicines Development Sciences</journal-title></journal-title-group><issn>2382-6363</issn><eissn>2382-6371</eissn><publisher><publisher-name>WHIOCE PUBLISHING PTE. LTD.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18063/JMDS.v10i4.1199</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title>The Diagnostic Threshold of High Viral Load Hepatitis B DNA Testing in Occult Infection Screening</title><url>https://artdesignp.com/journal/JMDS/10/4/10.18063/JMDS.v10i4.1199</url><author>LiuMeichen,LiuQing</author><pub-date pub-type="publication-year"><year>2025</year></pub-date><volume>10</volume><issue>4</issue><history><date date-type="pub"><published-time>2025-12-26</published-time></date></history><abstract>Subclinical hepatitis B infections often present with low viral loads that are easily missed by routine testing. High-sensitivity hepatitis B DNA testing provides critical technical support for their screening and diagnosis. This article focuses on core clinical application challenges of this testing technology, defining key target populations including post-antiviral treatment cirrhosis patients and high-risk groups with complications. It clarifies differences in inclusion criteria across medical scenarios while establishing unified standards. Based on technical characteristics and clinical evidence, a diagnostic cutoff of 10-2000 U/ml is proposed, along with validation and adjustment strategies for different populations. The analysis examines testing application boundaries, technical limitations, and clinical practice issues, providing actionable evidence to optimize screening processes for subclinical hepatitis B infections, improve diagnostic accuracy, and help reduce progression risks of related liver diseases.</abstract><keywords>highly sensitive hepatitis B DNA test, occult hepatitis B infection, target population, cut-off value, clinical application</keywords></article-meta></front><body/><back><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><p>[1] Li H, 2025, Clinical Features and Influencing Factors of Chronic Hepatitis B Patients with Low Viral Load. Journal of Transportation Medicine, 39(1):&amp;nbsp;47-49.
[2] Wang ZH, Shi SY, Niu CQ,&amp;nbsp;et al., 2024, Prognostic Analysis of Patients with Low Viral Load in Hepatitis B Cirrhosis Based on Highly Sensitive Detection. Shanxi Journal of Medicine, 53(6):&amp;nbsp;409-413.
[3] Li YF, 2023, The Application Value of High-Sensitivity PCR Detection of HBV-DNA in Patients with Chronic Hepatitis B and Low Viral Load. Modern Diagnosis and Treatment, 34(22):&amp;nbsp;3448-3449+3473.
[4] Pu D, Yu TT, Li LH,&amp;nbsp;et al., 2023, Analysis of High-Titer HBV DNA Detection in Serum from Low-Virus-Load Chronic Hepatitis B Patients in Kunming Region. Journal of Kunming Medical University, 44(1):&amp;nbsp;116-121.</p><pub-id pub-id-type="doi"/></element-citation></ref></ref-list></back></article>
